High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Patients with genotype 3 hepatitis C virus (G3-HCV) cirrhosis are very difficult to treat compared to patients with other HCV genotypes. The optimal treatment duration and drug regimen associated with ribavirin (RBV) remain unclear. To evaluate the efficacy and safety of daclatasvir (DCV)/sofosbuvir (SOF) plus a flat dose of 800 mg RBV (flat dose) compared to DCV/SOF without RBV or DCV/SOF plus an RBV dose based on body weight (weight-based) in G3-HCV patients with compensated or decompensated cirrhosis. Methods: We analyzed data for 233 G3 cirrhotic patients. Of these, 70 (30%), 87(37%) and 76 (33%) received SOF/DCV, SOF/DCV/RBV flat dose, and SOF/DCV/RBV weight-based dose, respectively. Treatment duration was 24 weeks. Sustained virological response (SVR) was evaluated at week 12 posttreatment (SVR12). Results: Overall, SVR12 was achieved in 220 out of 233 patients (94.4%). The SVR12 rate was lower in the DCV/SOF group than in the DCV/SOF/RBV flat-dose group and the DCV/SOF/RBV weight-based group (87.1% vs 97.7% and 97.4%, respectively, p=0.007). A higher incidence of anemia occurred in the DCV/SOF/RBV weight-based group compared to those in the other two groups (p<0.007). Conclusions: We found that the DCV/SOF/RBV flat-dose regimen is an effective treatment in terms of efficacy and safety in patients with G3-HCV compensated or decompensated cirrhosis. Therefore, antiviral regimens without RBV should be restricted only to naïve patients with G3-HCV compensated cirrhosis who have a clear contraindication for RBV.
Abstract
Background/Aims: Patients with genotype 3 hepatitis C virus (G3-HCV) cirrhosis are very difficult to treat compared to patients with other HCV genotypes. The optimal treatment duration and drug regimen associated with ribavirin (RBV) remain unclear. To evaluate the efficacy and safety of daclatasvir (DCV)/sofosbuvir (SOF) plus a flat dose of 800 mg RBV (flat dose) compared to DCV/SOF without RBV or DCV/SOF plus an RBV dose based on body weight (weight-based) in G3-HCV patients with compensated or decompensated cirrhosis. Methods: We analyzed data for 233 G3 cirrhotic patients. Of these, 70 (30%), 87(37%) and 76 (33%) received SOF/DCV, SOF/DCV/RBV flat dose, and SOF/DCV/RBV weight-based dose, respectively. Treatment duration was 24 weeks. Sustained virological response (SVR) was evaluated at week 12 posttreatment (SVR12). Results: Overall, SVR12 was achieved in 220 out of 233 patients (94.4%). The SVR12 rate was lower in the DCV/SOF group than in the DCV/SOF/RBV flat-dose group and the DCV/SOF/RBV weight-based group (87.1% vs 97.7% and 97.4%, respectively, p=0.007). A higher incidence of anemia occurred in the DCV/SOF/RBV weight-based group compared to those in the other two groups (p<0.007). Conclusions: We found that the DCV/SOF/RBV flat-dose regimen is an effective treatment in terms of efficacy and safety in patients with G3-HCV compensated or decompensated cirrhosis. Therefore, antiviral regimens without RBV should be restricted only to naïve patients with G3-HCV compensated cirrhosis who have a clear contraindication for RBV.
참고문헌 (19)
- Kawaguchi Y, "Interaction between hepatitis C virus and metabolic factors", World J Gastroenterol, 20, pp.2888~2901 (2014)
- Kanwal F, "HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U. S. Veterans with HCV", Hepatology, 60, pp.98~105 (2014)
- Leroy V, "Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease : a randomized phase III study(ALLY-3+)", Hepatology, 63, pp.1430~1441 (2016)
- Lontok E, "Closing in on the target : sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy", Clin Infect Dis, 56, pp.1466~1470 (2013)
- Nelson DR, "All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection : ALLY-3 phase III study", Hepatology, 61, pp.1127~1135 (2015)
- Zeuzem S, "Sofosbuvir and ribavirin in HCV genotypes 2 and 3", N Engl J Med, 370, pp.1993~2001 (2014)
- Feld JJ, "Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype 3 infection : results of the HCV-TARGET study", Clin Infect Dis, 63, pp.776~783 (2016)
- Cornberg M, "Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection", Aliment Pharmacol Ther, 45, pp.688~700 (2017)
- European Association for Study of Liver, "EASL clinical practice guidelines : management of hepatitis C virus infection", J Hepatol, 60, pp.392~420 (2014)
- Alonso S, "Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis : results of a multicenter real-life cohort", J Viral Hepat, 24, pp.304~311 (2017)
- Herzer K, "Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease", Transpl Int, 30, pp.243~255 (2017)
- Hézode C, "Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme", Liver Int, 37, pp.1314~1324 (2017)
- Curry MP, "Sofosbuvir and velpatasvir for patients with HCV infection", N Engl J Med, 374, pp.1688~ (2016)
- Pianko S, "Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection : a randomized trial", Ann Intern Med, 163, pp.809~817 (2015)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2018", J Hepatol, 69, pp.461~511 (2018)
- Wyles D, "Glecaprevir", pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and, Hepatology, pp.2018, 67[DOI]
- Reig M, "Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy", J Hepatol, 65, pp.719~726 (2016)
- Cabibbo G, "Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study", Aliment Pharmacol Ther, 46, pp.688~695 (2017)
- Chinchilla-López P, "The direct-acting antivirals for hepatitis C virus and the risk for hepatocellular carcinoma", Ann Hepatol, 16, pp.328~330 (2017)